Terms: = Lung cancer AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS AND Treatment
93 results:
1. Evolutionary trajectories of small cell lung cancer under therapy.
George J; Maas L; Abedpour N; Cartolano M; Kaiser L; Fischer RN; Scheel AH; Weber JP; Hellmich M; Bosco G; Volz C; Mueller C; Dahmen I; John F; Alves CP; Werr L; Panse JP; Kirschner M; Engel-Riedel W; Jürgens J; Stoelben E; Brockmann M; Grau S; Sebastian M; Stratmann JA; Kern J; Hummel HD; Hegedüs B; Schuler M; Plönes T; Aigner C; Elter T; Toepelt K; Ko YD; Kurz S; Grohé C; Serke M; Höpker K; Hagmeyer L; Doerr F; Hekmath K; Strapatsas J; Kambartel KO; Chakupurakal G; Busch A; Bauernfeind FG; Griesinger F; Luers A; Dirks W; Wiewrodt R; Luecke A; Rodermann E; Diel A; Hagen V; Severin K; Ullrich RT; Reinhardt HC; Quaas A; Bogus M; Courts C; Nürnberg P; Becker K; Achter V; Büttner R; Wolf J; Peifer M; Thomas RK
Nature; 2024 Mar; 627(8005):880-889. PubMed ID: 38480884
[TBL] [Abstract] [Full Text] [Related]
2. Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts.
Zhang L; Wang Y; Wang L; Wang M; Li S; He J; Ji J; Li K; Cao L
J Mol Med (Berl); 2024 Jan; 102(1):69-79. PubMed ID: 37978056
[TBL] [Abstract] [Full Text] [Related]
3. I-cbp112 declines overexpression of ATP-binding cassette transporters and sensitized drug-resistant MDA-MB-231 and A549 cell lines to chemotherapy drugs.
Strachowska M; Gronkowska K; Sobczak M; Grodzicka M; Michlewska S; Kołacz K; Sarkar T; Korszun J; Ionov M; Robaszkiewicz A
Biomed Pharmacother; 2023 Dec; 168():115798. PubMed ID: 37913733
[TBL] [Abstract] [Full Text] [Related]
4. [Impact of immunotherapy on the therapeutic strategy for the management of stage I non-small cell lung cancer: The radiation oncologist's point of view].
Khalifa J
Cancer Radiother; 2023 Sep; 27(6-7):653-658. PubMed ID: 37573193
[TBL] [Abstract] [Full Text] [Related]
5. Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell lung cancer, ETCTN 10399.
Gentzler RD; Villaruz LC; Rhee JC; Horton B; Mock J; Hanley M; Kim K; Rudek MA; Phelps MA; Carducci MA; Piekarz R; Park KS; Bullock TN; Rudin CM
Oncologist; 2023 Nov; 28(11):1007-e1107. PubMed ID: 37555284
[TBL] [Abstract] [Full Text] [Related]
6. Repeatedly next-generation sequencing during treatment follow-up of patients with small cell lung cancer.
JiaXin Y; XiaoFeng C; PengFei C; Songchen Z; Ziling L
Medicine (Baltimore); 2023 Jun; 102(26):e34143. PubMed ID: 37390276
[TBL] [Abstract] [Full Text] [Related]
7. Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Qureshi R; Picon-Ruiz M; Sho M; Van Booven D; Nunes de Paiva V; Diaz-Ruano AB; Ince TA; Slingerland J
Cell Rep; 2022 Nov; 41(7):111672. PubMed ID: 36384125
[TBL] [Abstract] [Full Text] [Related]
8. Pharmacological targeting of cbp/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells.
Ansari MSZ; Stagni V; Iuzzolino A; Rotili D; Mai A; Del Bufalo D; Lavia P; Degrassi F; Trisciuoglio D
Cancer Gene Ther; 2023 Jan; 30(1):124-136. PubMed ID: 36117234
[TBL] [Abstract] [Full Text] [Related]
9. Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway.
Zhang T; Xia W; Song X; Mao Q; Huang X; Chen B; Liang Y; Wang H; Chen Y; Yu X; Zhang Z; Yang W; Xu L; Dong G; Jiang F
J Hematol Oncol; 2022 Aug; 15(1):114. PubMed ID: 35982471
[TBL] [Abstract] [Full Text] [Related]
10. The Effect and Mechanism of Curcumin Combined with Carboplatin Chemotherapy Promoting on Apoptosis of lung cancer HCC827 Cells.
Huang L; He X; Zuo X
J Immunol Res; 2022; 2022():1932692. PubMed ID: 35979255
[TBL] [Abstract] [Full Text] [Related]
11. Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.
Liu C; Liu C; Liao J; Yin JC; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Shao Y; Wang J
Lung Cancer; 2022 Sep; 171():18-25. PubMed ID: 35870258
[TBL] [Abstract] [Full Text] [Related]
12. Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.
Principe DR
Sci Rep; 2022 Jul; 12(1):11490. PubMed ID: 35798829
[TBL] [Abstract] [Full Text] [Related]
13. Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC.
Tao Z; Kuai X; Wang G; Liu S; Liu K; Zhang H; Xia S; Zhu H
Drug Deliv; 2022 Dec; 29(1):1571-1581. PubMed ID: 35612299
[TBL] [Abstract] [Full Text] [Related]
14. Effects of artesunate on the malignant biological behaviors of non-small cell lung cancer in human and its mechanism.
Hu P; Ni C; Teng P
Bioengineered; 2022 Mar; 13(3):6590-6599. PubMed ID: 35361045
[TBL] [Abstract] [Full Text] [Related]
15. Pan-cancer landscape of
Kelly AD; Murugesan K; Kuang Z; Montesion M; Ross JS; Albacker LA; Huang RSP; Lin DI; Demirci U; Creeden J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815356
[TBL] [Abstract] [Full Text] [Related]
16. [D-cbp study: Evaluation of lung cancer management times].
Deshayes S; Leite Ferreira D; Madelaine J; Oulkhouir Y; Campbell K; Fouquet H; Teulier S; Magnier R; Heyndrickx M; Lerouge D; Bergot E; Justet A
Rev Mal Respir; 2021 Nov; 38(9):894-903. PubMed ID: 34756617
[TBL] [Abstract] [Full Text] [Related]
17. Oxaliplatin facilitates tumor-infiltration of T cells and natural-killer cells for enhanced tumor immunotherapy in lung cancer model.
Xin M; Lin D; Yan N; Li H; Li J; Huang Z
Anticancer Drugs; 2022 Feb; 33(2):117-123. PubMed ID: 34561996
[TBL] [Abstract] [Full Text] [Related]
18. A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.
Lin J; Wang X; Zhang C; Bu S; Zhao C; Wang H
Front Immunol; 2021; 12():606027. PubMed ID: 34248926
[TBL] [Abstract] [Full Text] [Related]
19. Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer.
Inoue Y; Nikolic A; Farnsworth D; Shi R; Johnson FD; Liu A; Ladanyi M; Somwar R; Gallo M; Lockwood WW
Elife; 2021 Jun; 10():. PubMed ID: 34121659
[TBL] [Abstract] [Full Text] [Related]
20. CITED4 enhances the metastatic potential of lung adenocarcinoma.
Zhang L; Wang Y; Sha Y; Zhang B; Zhang R; Zhang H; Xu S; Wang H; Xu Y; Chen Y; Zhao X; Zhu J; Zhang Z; Wang C
Thorac Cancer; 2021 May; 12(9):1291-1302. PubMed ID: 33759374
[TBL] [Abstract] [Full Text] [Related]
[Next]
